EBOO / Extracorporeal Blood Oxygenation and Ozonation Therapy

EBOO or Extracorporeal Blood Oxygenation and Ozonation is a unique hemofiltration-like procedure. EBOO combines modern membrane dialysis used to treat heart, kidney and liver failure with, ozone therapy. Extensive testing of EBOO has revealed no toxicity or side effects in sheep or human volunteers. EBOO is designed to amplify the therapeutic benefits reported of Auto hemotherapy by treating a greater volume of blood (4 litres/hr) at a lower ozone concentration .

A clinical trial of EBOO showed it to be more effective in the treatment of peripheral artery disease than prostacyclin. Further trials are currently underway for heart disease and stroke patients for which preliminary reports of ozone treatment have been positive. EBOO is also reported to have remedied necrotizing fasciitis, an often fatal bacterial infection resistant to antibiotics. Ozone's anti-bacterial and viral properties have been employed successfully in water purification. The International Society of Blood Purification has recognized EBOO as warranting clinical investigation as a viral load reducing treatment. Ozone has been shown to disinfect extracorporeal blood of viruses.

Due to the oxidative nature of ozone, the filter components and membranes will block up and inhibit the effective exchange of gas, possibly releasing toxic compounds into the circulating blood. An economical ozone resistant gas exchange device (L001) has been specifically designed for the ozonation of human blood during extra-corporeal circulation. EBOO, also known as extracorporeal blood oxygenation and ozonation treatment, exposes blood to oxygen (O2) mixed with ozone (O3). The blood is returned to the patient in under 30 minutes. Studies indicate no ill effects from the treatment, and reports indicate that the benefits from this type of therapy include lowered total cholesterol and low-density lipoprotein levels, along with enhanced antioxidant activity.


Improved Vasodilatation (stretching of a vessel/arteriole beyond its normal dimension leading to increased blood flow) in ischemic areas.
Reduced Hypoxia (reduction of oxygen carrying capacity of blood)
Induced Neo-Angiogenesis (formation of new blood vessels) due to enhanced release of nitric oxide.
Heart, Kidney & Liver failureArtery Blokage Diseases (Coronary, leg, neck arteries) – Patients with stents accepted
Lipid Disorders of any severity and in particular triglycerides elevation not responding to therapy
Kidney Disease in all stages including patients on dialysis procedures
Diabetes Complications: Retinopathy, Neuropathy, nNphropathy
Virus Diseases: Herpes all types, HIV (AIDS), Hepatitis B, Hepatitis C, CMV
Liver Disorders including Cirrhosis of the liver, irrespective of the cause
Lung Tuberculosis multiple-drug resistant type
Cancer all types – improvement in quality of life
Chemotherapy dose can be halved thus reducing the adverse effects
MRSA (Methicillinb Reesistant Staphylococcus Aureus) & other infections
ARMD – Age Related Mascular Degeneration
Parkinsons Disease (early stage RESPONDS BETTER)
Rheumatoid Arthritis
Osteoarthritis(degenerative or other causes)
Gout Arthritis/Hyperuricemia irrespective of the cause-uric acid level is reduced
Lung Interstitial Fibrosis disease - generally progressive disorder
Calciphylaxis non-healing ulcers (in long term haemodialysis patients)
Diabetic Foot/LEG non-healing wounds (avoids amputation)
Polyneuropathy due to any cause (motor and sensory types including demyelinating type)
Chronic Illness due to any cause that has not responded to other treatments
Brain Disorders due to inadequate blood supply including 'brain fog'
Lyme Disease
Multiple Lipoma /Medelung's Disease
Lichen Planus